GLPwatch
Ozempic for Bipolar disorder
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is not FDA-approved for bipolar disorder, and any use for this condition is off-label or investigational. The listed research includes case reports and observational studies on psychiatric adverse events and weight management in patients with bipolar disorder or antipsychotic use, but does not establish efficacy for treating the condition.
AI summary of the sources below.
| Drug | Ozempic (semaglutide) |
|---|---|
| Condition | Bipolar disorder |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Ozempic is not FDA-approved for bipolar disorder; the research below reflects investigational or off-label study only.
Research on semaglutide for bipolar disorder (7)
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.
- Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.